## Intrauterine delivery of progestogen in the peri- and postmenopausal women

ESHRE Campus meeting 6.-7.10.2008

Oskari Heikinheimo Helsinki University Central Hospital Helsinki, Finland oskari.heikinheimo@helsinki.fi



## Outline of the presentation

- Intrauterine delivery of progestins Introduction to LNG-IUS
  - Other options..
  - Studies assessing the use of LNG-IUS during peri- and postmenopause
  - Acceptability
  - Bleeding patterns
  - Safety

•

- Endometrium
   General health
  Long-term use of LNG-IUS
- 'Clinicians view...
- Future prospects

## Levonorgestrel releasing IUS - Mirena®

- Intrauterine release of 20µg LNG/d
- Approved for up to 5 years
- Pearl-index ~ 0.1 ٠
  - 12% of Scandinavian women used Mirena® in 2007
- Effective in the treatment of heavy menstrual bleeding
  - Rate of oligo-amenorrhea ~ 20%
  - Reduces the need for hysterectomy
- Local progestin delivery as a part of HRT

# Current use and approval status of Mirena<sup>®</sup>

#### • Currently >7.5 million Mirena<sup>®</sup> users

Indication	# countries
Contraception	122
Heavy menstrual bleeding	115
Endometrial protection during ET	106

## Current status of LNG-IUS use in Finland

- Mirena<sup>®</sup> on the market since 1990 - 15% Finnish women use Mirena<sup>®</sup>
- Effects on ob&gyn speciality
  - Rate of hysterectomy  $\downarrow$
  - Rate of surgical sterilization  $\downarrow$
- Increasing use as a part of HRT - How much ??

### Other alternatives...

Wildemeersch, Contraception 2007

- Frameless FibroPlant LNG-IUS
  - 3 or 4.5 cm long, Ø 1.6 device, releasing 14 or 20µg of LNG/day
    Anchored to uterine fundus
  - Anchored to uterine fundus
- Femilis<sup>™</sup> and Femilis<sup>™</sup> slim LNG-IUS
  - 2.4 x 3cm or 2.0 x 3cm devices 20µg of LNG/day
- Manufactured by Contrel Research, Belgium
- Both tested also in HRT
  - Similar results as those with  $\ensuremath{\mathsf{Mirena}}\xspace{\mathbbmath {B}}$

## How does LNG-IUS work?

- 1. Endometrial effects most important
- 2. Viscosity of cervical mucus increased
- 3. Inhibition of sperm motility
- 4. In addition, some
  Foreign body reaction
  Effects on ovarian function



Endometrial effects of Mirena 1. Atrophy of the glands -Inactivation of IGF-I-system -Steroid receptors ↓ 2. Decidualization of the stroma

# Local is logical• LNG concentrations during the use of<br/>LNG-IUS (Nilsson et al., 1982)• Endometrium470- 1500 ng/g• Myometrium1.8-2.4 ng/g• Plasma0.1-0.2 ng/ml

## Search strategy

- PubMed search using the terms
  - LNG-IUS/IUD and menopaus\*
  - LNG-IUS/IUD and HRT
  - LNG-IUS/IUD and hormone replacement therapy
- Personal knowledge of the field
- Cross referencing

# Summary of the different studies

#### • Perimenopausal women

- Suhonen et al., Acta Ob&Gyn Scand, 1997
- Hampton et al., Hum Reprod, 2005

#### Postmenopausal women

- Suvanto-Luukkonen et al., F&S, 1999
- Raudaskoski et al., BJOG, 2002

# Practical points - Insertion at peri- or postmenopause

 Hampton et al., 2005
 Insertion successful in 98% (80/82)

## – n=40 • Easy 65% • Difficult 35%

- Easy 77%
  Difficult 23%
- Dilatation in 30%Pain
  - ain Na asia 24%
  - No pain 24%
  - Mild 56%
  - Moderate 16%Severe 3%
- 'Facilitating intervention' in 30%
  - Pain
  • No pain 48%

• Varila et al., 2001

- No pain 48%Mild 33%
- Moderate 18%
- Severe 3%


## Effects on endometrial histology

Ref	Estrogen used	Baseline	1-5 years
Suhonen et al., 1997	E <sub>2</sub> releasing implants, 50µg E <sub>2</sub> patch OR 2mg E <sub>2</sub> valerate		Glandular atrophy, decidualized stroma. Weak E2 effect in 24%
Suvanto- Luukkonen et al., 1999	1.5 mg E <sub>2</sub> gel		Epithelial atropy, decidualized stroma in 100%
Varila et al., 2001	50µg E <sub>2</sub> patch OR 2mg E <sub>2</sub> valerate		'Strong' progestin effect in 97%
Hampton et al., 2005	1.25 - 0.625 mg CEE orally	Proliferative in 45% Inadequate sample 26%	Non-proliferative in >95%



	ales of alle	rates of amenorrhea			
Ref	Comment	1 year	3 years	5 years	
Suhonen et al., 1997	Peri- and postmenopausal women	76%	79%	N.A.	
Suvanto- Luukkonen et al., 1999	Post-menopausal women	80%	80%	80%	
Varila et al., 2001	Symptomatic perimenopausal women	90%			
Hampton et al., 2005	Symptomatic perimenopausal women >40y and FSH >15 IU/L, OR >47y. <i>n</i> =82	54%		93%	







Reference	Continuation rate at 5 years
Suvanto-Luukkonen et al., 1999	60%
Hampton et al., 2005	80%



	•	Se of LNG-IUS	5
- Swedis		al (LNG-IUS vs Nova] e offered to continue the u	-
1. Mirena	2. Mirena	3. Mirena	
Û	$\hat{\mathbb{T}}$	Û	
300	5y 7y 100 82	12y 69	


High rate of amenorrhea during long-term use of LNG-IUS Rönnerdag et al. Acta Obst Gyn Scand 1999		
Bleeding pattern	End of 1 <sup>st</sup> LNG-IUS	During 2 <sup>nd</sup> LNG-IUS
Regular	70%	28%
Infrequent	4%	12%

26%

60%

Amenorrhea



## Clinicians view...

- HRT with systemic E<sub>2</sub> and intrauterine progestin administration often ideal
  - High rate of amenorrhea
  - Tailored administration of E<sub>2</sub>
- Long term patient-doctor relationship important
  - Start the transition to intrauterine contraception during late reproductive years

## Practical points...

- How to diagnose menopause in LNG-IUS user with scanty / no bleeding?
  - Symptoms
  - FSH measurements rarely needed
  - Ovarian US (?)
  - Trial of E<sub>2</sub> therapy
- Does the use of LNG-IUS alleviate menopausal symptoms?

## Intrauterine progestin in HRT - long term health consequences?




- No data on the risk of
   Breast cancer
- Cardiovascular diseaseRegistry based studies
  - on-going in – Denmark
  - Denmar
     Finland

Contraceptive use of LNG-IUS vs. the risk of breast cancer Backman et al., Ob&Gyn, 2005

- Postmarketing study of 17.360 LNG-IUS users
   Finnish Cancer Registry
- Finnish Cancer Registr data on breast cancer

 No difference in the incidence of breast cancer in LNG-IUS users vs general female population



#### Effects of LNG-IUS on breast density and proliferation *Lundström et al., F&S, 2006*

- 20 postmenopausal women receiving 2mg E<sub>2</sub> and LNG-IUS for 18 mo
- Mammographic density & breast proliferation in FNB specimens evaluated
- Effect on breast density
   Increase in 15% (3/20)
  - No increase in 85%
- No increase in MIB-1 positive breast cells in FNB specimens

## Effect of LNG-IUS on serum lipids (Raudaskoski et al., BJOG 2002)

• 55 postmenopausal women using LNG-IUS and 2mg E<sub>2</sub> orally for 18 months

	Baseline	6 mo	12 mo
Total chol	5.89 mmol/l	↓ 9%	↓ 8%
LDL	3.64 mmol/l	↓ 14%	↓ 11%
HDL	1.64 mmol/l	$\leftrightarrow$	$\leftrightarrow$
Triglycer	1.12 mmol/l	$\leftrightarrow$	$\leftrightarrow$

# Use of LNG-IUS in endometrial hyperplasia (Varma et al., 2008)

- Prospective study on LNG-IUS treatment of endometrial hyperplasia
  - n=105 women
  - 35% pre- and 65% postmenopausal
  - Histologial sampling at regular intervalsOutcome based on histology at 1 and 2 years
- Results
  - Non-atypical hyperplasia regression in 92% (88/96)
  - Atypical hyperplasia regression in 67% (6/9)
- LNG-IUS is an alternative to oral progestin / hysterectomy in cases on endometrial hyperplasia

## Future prospects - smaller devices releasing lower doses of LNG

- Randomized comparison of 10 vs 20µg
  - releasing LNG-IUS (Raudaskoski et al., BJOG 2002)
     Similar rates of amennorhea and endometrial suppression

	10µg IUS	Mirena®
Dimensions	2.8 x 2.8 cm	3.2 x 3.2 cm
Diameter	2.3 mm	3.2 mm
Insertion easy	70 %	46 %

## Conclusions

#### Combination of systemic E<sub>2</sub> and intrauterine release of LNG is a often an ideal option for HRT

- Effective suppression of endometrium
- High rate of amenorrhea
- High continuation rate
- Long-term effects on general health still unknown

